Antibody-drug conjugates hitting this target abound.
ApexOnco Front Page
Recent articles
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
